Impact of bleeding assessment and adjudication methodology on event rates and clinical trial outcomes: insights from the HORIZONS-AMI trial

EuroIntervention 2018;14:e580-e587 published online April 2018 published online e-edition August 2018. DOI: 10.4244/EIJ-D-18-00131

Ioanna Kosmidou1,2, MD, PhD; Gary S. Mintz1, MD; Tannas Jatene3, MD; Monica Embacher1, MD; Björn Redfors1, MD; S. Chiu Wong4, MD; Ovidiu Dressler1, MD; Roxana Mehran1,5, MD; Ori Ben-Yehuda1,4, MD; Paul L. Jenkins1, PhD; Gregg W. Stone1,4*, MD

1. Clinical Trials Center, Cardiovascular Research Foundation, New York, NY, USA; 2. The Heart Center, St. Francis Hospital, Roslyn, NY, USA; 3. Anis Rassi Hospital, Goiania, Brazil; 4. New York-Presbyterian Hospital/Columbia University Medical Center, Ne

Aims: Bleeding is a major safety outcome in cardiovascular trials. The present study assessed the impact of the adjudication process of bleeding events on three-year outcomes in the Harmo

Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

bare metal stentbleedingclinical research

Coronary interventionsSTEMI

Share on Facebook Share on Twitter Share on Linkedin

Impact of bleeding assessment and adjudication methodology on event rates and clinical trial outcomes: insights from the HORIZONS-AMI trial

Read next article

Latest news

Coronary

Valvular disease

Heart failure

Peripheral

Hypertension

Stroke